Efficacy of peginterferon α-2a in treatment of chronic hepatitis B resistant to multiple nucleos(t)ide analogues
10.3969/j.issn.1001-5256.2016.04.016
- VernacularTitle:聚乙二醇干扰素α-2a治疗多种核苷和核苷酸类药物耐药慢性乙型肝炎的效果观察
- Author:
Long YANG
1
;
Yang YANG
;
Xuehu JIANG
Author Information
1. Department of Infectious Diseases, Shanghai Corps Hospital of Chinese People′s Armed Police Forces, Shanghai 201103, China
- Publication Type:Research Article
- Keywords:
hepatitis B, chronic；antiviral agents；polyethylene glycols;
interferon alfa-2a
- From:
Journal of Clinical Hepatology
2016;32(4):691-694
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the efficacy of peginterferon alfa-2a (PEG-IFN α-2a) in the treatment of HBeAg-positive chronic hepatitis B (CHB) resistant to multiple nucleos(t)ide analogues (NAs). MethodsA total of 120 patients with HBeAg-positive CHB resistant to multiple nucleos(t)ide analogues who were hospitalized or treated in the outpatient department in our hospital from August 2009 to February 2014 were randomly divided into two groups, with 60 patients in each group. The patients in the treatment group stopped NAs and were given PEG-IFNα-2a for 48 weeks, and those in the control group received PEG-IFNα-2a for 48 weeks in addition to the original therapeutic regimen with NAs. The changes in the serological markers of hepatitis B and HBV DNA were observed at weeks 24 and 48 of treatment and at 24 weeks after drug discontinuation. The chi-square test was used for comparison of categorical data between groups, while comporison of continuous data was mode by t test. ResultsThe patients in both groups achieved a satisfactory outcome. The serum HBeAg clearance rate, HBeAg seroconversion rate, HBV DNA clearance rate, and HBsAg clearance rate showed no significant differences between the two groups at weeks 24 and 48 of treatment and at 24 weeks after treatment (all P＞0.05). The adverse events that occurred during PEG-IFNα-2a treatment were pyrexia, headache, inflammation at the injection site, diarrhea, neutropenia, anemia, and depression, and the disease is not serious. ConclusionPEG-IFNα-2a is safe and effective in the treatment of CHB resistant to multiple NAs, and the patients can convert to PEG-IFNα-2a directly as their antiviral therapy.
